1. Grayson M. Bladder cancer. Nature 2017;551:S33.
2. Hurst C, Rosenberg J, Knowles M. SnapShot: Bladder Cancer. Cancer Cell 2018;34:350- e1.
3. Sacher AG, St Paul M, Paige CJ, Ohashi PS. Cytotoxic CD4(+) T Cells in Bladder Cancer-A New License to Kill. Cancer Cell 2020;38:28-30.
4. Oh DY, Kwek SS, Raju SS, et al. Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell 2020;181:1612-25 e13.
5. Deng W, Fernandez A, McLaughlin SL, Klinke DJ, 2nd. WNT1-inducible signaling pathway protein 1 (WISP1/CCN4) stimulates melanoma invasion and metastasis by promoting the epithelial-mesenchymal transition. J Biol Chem 2019;294:5261-80.
6. Jing D, Zhang Q, Yu H, Zhao Y, Shen L. Identification of WISP1 as a novel oncogene in glioblastoma. Int J Oncol 2017;51:1261-70.
7. Wang QY, Feng YJ, Ji R. High expression of WISP1 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2020;24:10445-51.
8. Chen YZ, Sun DQ, Zheng Y, et al. WISP1 silencing confers protection against epithelial-mesenchymal transition of renal tubular epithelial cells in rats via inactivation of the wnt/beta-catenin signaling pathway in uremia. J Cell Physiol 2019;234:9673-86.
9. Gaudreau PO, Clairefond S, Class CA, et al. WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. Oncoimmunology 2019;8:e1581545.
10. Liao X, Bu Y, Xu Z, et al. WISP1 Predicts Clinical Prognosis and Is Associated With Tumor Purity, Immunocyte Infiltration, and Macrophage M2 Polarization in Pan-Cancer. Front Genet 2020;11:502.
11. Tao W, Chu C, Zhou W, et al. Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma. Nat Commun 2020;11:3015.
12. Harb-de la Rosa A, Acker M, Kumar RA, Manoharan M. Epigenetics application in the diagnosis and treatment of bladder cancer. Can J Urol 2015;22:7947-51.
13. Hou G, Xu W, Jin Y, Wu J, Pan Y, Zhou F. MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D. Biochem Biophys Res Commun 2019;519:747-53.
14. Zhao X, Li D, Zhao ST, et al. MiRNA-616 aggravates the progression of bladder cancer by regulating cell proliferation, migration and apoptosis through downregulating SOX7. Eur Rev Med Pharmacol Sci 2019;23:9304-12.
15. Sekar D. miRNA 21: a novel biomarker in the treatment of bladder cancer. Biomark Med 2020;14:1065-7.
16. Yin XH, Jin YH, Cao Y, et al. Development of a 21-miRNA Signature Associated With the Prognosis of Patients With Bladder Cancer. Front Oncol 2019;9:729.
17. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007;9:166-80.
18. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
19. Lanczky A, Nagy A, Bottai G, et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat 2016;160:439-46.
20. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015;4.
21. Zhang LH, Wang Y, Fan QQ, et al. Up-regulated Wnt1-inducible signaling pathway protein 1 correlates with poor prognosis and drug resistance by reducing DNA repair in gastric cancer. World J Gastroenterol 2019;25:5814-25.
22. Lee HL, Chiou HL, Wang SS, et al. WISP1 genetic variants as predictors of tumor development with urothelial cell carcinoma. Urol Oncol 2018;36:160 e15- e21.
23. Zheng Y, Chen CJ, Lin ZY, et al. Circ_KATNAL1 regulates prostate cancer cell growth and invasiveness through the miR-145-3p/WISP1 pathway. Biochem Cell Biol 2020;98:396-404.
24. Mao A, Tang J, Tang D, et al. MicroRNA-29b-3p enhances radiosensitivity through modulating WISP1-mediated mitochondrial apoptosis in prostate cancer cells. J Cancer 2020;11:6356-64.
25. Wang L, Sun J, Cao H. MicroRNA-384 regulates cell proliferation and apoptosis through directly targeting WISP1 in laryngeal cancer. J Cell Biochem 2019;120:3018-26.
26. Pommier A, Varilh J, Bleuse S, et al. miRNA repertoires of cystic fibrosis ex vivo models highlight miR-181a and miR-101 that regulate WISP1 expression. J Pathol 2020.
27. Oto J, Plana E, Fernandez-Pardo A, et al. Identification of miR-29c-3p as a Robust Normalizer for Urine microRNA Studies in Bladder Cancer. Biomedicines 2020;8.
28. Fang R, Huang Y, Xie J, Zhang J, Ji X. Downregulation of miR-29c-3p is associated with a poor prognosis in patients with laryngeal squamous cell carcinoma. Diagn Pathol 2019;14:109.
29. Hu Z, Cai M, Zhang Y, Tao L, Guo R. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway. Cell Cycle 2020;19:193-206.
30. Wang H, Fu L, Wei D, et al. MiR-29c-3p Suppresses the Migration, Invasion and Cell Cycle in Esophageal Carcinoma via CCNA2/p53 Axis. Front Bioeng Biotechnol 2020;8:75.
31. Yu G, Zhou H, Xu K, Meng L, Lang B. [Mir-29c-3p targeting TUG1 affects migration and invasion of bladder cancer cells by regulating CAPN7 expression]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:1325-31.
32. Liu Z, Zhang H, Sun L, Zhu K, Lang W. miR-29c-3p Increases Cell Viability and Suppresses Apoptosis by Regulating the TNFAIP1/NF-kappaB Signaling Pathway via TNFAIP1 in Abeta-Treated Neuroblastoma Cells. Neurochem Res 2020;45:2375-84.